European Academy of Dermatology and Venereology Congress
Phase 3 data support nemolizumab for atopic dermatitis, prurigo nodularis treatment
Galderma has announced positive data from three phase 3 studies that evaluated nemolizumab for the treatment of atopic dermatitis and prurigo nodularis, according to a company press release.
52-week data shows vitiligo improvement with povorcitinib
Patients with vitiligo treated with oral povorcitinib showed significant repigmentation of the face and body, Incyte announced in a press release.
Rinvoq exhibits ‘acceptable benefit and risk profile’ for AD treatment up to 140 weeks
Rinvoq showed long-term efficacy and safety up to 140 weeks in the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, AbbVie announced in a press release.
Opzelura effective, well tolerated in children aged at least 2 years with atopic dermatitis
Opzelura achieved significant efficacy for the treatment of atopic dermatitis in children aged as young as 2 years, Incyte announced in a press release.
Bimekizumab reduces disease severity among patients with hidradenitis suppurativa
New pooled results from the BE HEARD phase 3 trials show bimekizumab reduces disease severity in patients with moderate to severe hidradenitis suppurativa, according to a UCB press release.
Coacillium solution sustains adolescent alopecia areata improvement post-treatment
Coacillium solution 22.25% improved moderate to severe alopecia in children and adolescents while retaining results post-treatment, according to a study presented at the European Academy of Dermatology and Venereology 2023 Congress.
Patient-reported outcomes favor roflumilast vs. vehicle in scalp, body psoriasis treatment
New results, including patient-reported outcome data, from the phase 3 ARRECTOR trial show roflumilast foam 0.3% continues to improve scalp and body psoriasis in adults, Arcutis announced in a press release.
Amlitelimab shows promise as treatment for moderate to severe atopic dermatitis
Amlitelimab exhibited clinically meaningful efficacy over 24 weeks in the treatment of adults with moderate to severe atopic dermatitis, according to study results presented at the European Academy of Dermatology and Venereology 2023 Congress.
Phase 3 results show Vtama rapidly reduces itch in children, adults with atopic dermatitis
Dermavant Sciences has announced new “highly favorable” phase 3 pruritus data for Vtama cream for the treatment of moderate to severe atopic dermatitis in adults and children aged as young as 2 years, according to a press release.
Data show Sotyktu maintains treatment outcomes for plaque psoriasis at 3 years
Three-year data from the POETYK PSO long-term extension trial of Sotyktu showed consistent efficacy and safety for the treatment of adults with moderate to severe plaque psoriasis, Bristol Myers Squibb announced in a press release.